Eupraxia Pharmaceuticals (TSE:EPRX)
TSX:EPRX
Want to see TSE:EPRX full AI Analyst Report?
Total Valuation
Eupraxia Pharmaceuticals has a market cap or net worth of C$596.96M. The enterprise value is C$168.31M.
Market CapC$596.96M
Enterprise ValueC$168.31M
Share Statistics
Eupraxia Pharmaceuticals has 65,326,950 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding65,326,950
Owned by Insiders10.65%
Owned by Institutions25.37%
Financial Efficiency
Eupraxia Pharmaceuticals’s return on equity (ROE) is -0.48 and return on invested capital (ROIC) is -48.56%.
Return on Equity (ROE)-0.48
Return on Assets (ROA)-0.46
Return on Invested Capital (ROIC)-48.56%
Return on Capital Employed (ROCE)-0.49
Revenue Per Employee0.00
Profits Per Employee-1.17M
Employee Count33
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Eupraxia Pharmaceuticals is ―. Eupraxia Pharmaceuticals’s PEG ratio is -0.21.
PE Ratio―
PS Ratio0.00
PB Ratio5.04
Price to Fair Value5.04
Price to FCF-13.91
Price to Operating Cash Flow-11.54
PEG Ratio-0.21
Income Statement
In the last 12 months, Eupraxia Pharmaceuticals had revenue of 0.00 and earned -39.25M in profits. Earnings per share was -1.05.
Revenue0.00
Gross Profit-241.88K
Operating Income-39.11M
Pretax Income-39.26M
Net Income-39.25M
EBITDA-38.86M
Earnings Per Share (EPS)-1.05
Cash Flow
In the last 12 months, operating cash flow was -31.41M and capital expenditures -727.56K, giving a free cash flow of -32.14M billion.
Operating Cash Flow-31.41M
Free Cash Flow-32.14M
Free Cash Flow per Share-0.49
Dividends & Yields
Eupraxia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.01
52-Week Price Change53.04%
50-Day Moving Average9.59
200-Day Moving Average9.57
Relative Strength Index (RSI)48.95
Average Volume (3m)53.43K
Important Dates
Eupraxia Pharmaceuticals upcoming earnings date is Aug 7, 2026, TBA (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 7, 2026
Ex-Dividend Date―
Financial Position
Eupraxia Pharmaceuticals as a current ratio of 15.12, with Debt / Equity ratio of 1.46%
Current Ratio15.12
Quick Ratio15.12
Debt to Market Cap<0.01
Net Debt to EBITDA2.07
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Eupraxia Pharmaceuticals has paid 19.42K in taxes.
Income Tax19.42K
Effective Tax Rate>-0.01
Enterprise Valuation
Eupraxia Pharmaceuticals EV to EBITDA ratio is -8.54, with an EV/FCF ratio of -11.20.
EV to Sales0.00
EV to EBITDA-8.54
EV to Free Cash Flow-11.20
EV to Operating Cash Flow-11.43
Balance Sheet
Eupraxia Pharmaceuticals has C$138.98M in cash and marketable securities with C$2.01M in debt, giving a net cash position of C$136.97M billion.
Cash & Marketable SecuritiesC$138.98M
Total DebtC$2.01M
Net CashC$136.97M
Net Cash Per ShareC$2.10
Tangible Book Value Per ShareC$2.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Eupraxia Pharmaceuticals is C$23.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$23.10
Price Target Upside137.12% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-34.19%